A presentation given recently by Medicenna Therapeutics Corp. highlighted preclinical data for the company’s new anti-PD1-IL-2 BiSKIT (Bifunctional SuperKine for ImmunoTherapy) candidate, MDNA-223, being developed as a anticancer therapeutic candidate.
Sosei Group Corp. and Verily Life Sciences LLC, an Alphabet company, have announced the successful validation and nomination of a first G protein-coupled receptor (GPCR) target into early drug discovery for immune-mediated diseases with an initial indication focus of inflammatory bowel disease (IBD).
Researchers from MD Anderson Cancer Center recently presented the discovery and preclinical evaluation of LLO-CD47, a novel protein-antibody conjugate linking anti-CD47 to Listeriolysin O (LLO), a pore-forming protein secreted by Listeria monocytogenes to escape lysosomes.
The broadest view of post-mortem brains in Alzheimer’s disease (AD) has unveiled the genome, transcriptome and epigenome alterations of this neurodegenerative condition. The coordinated research, directed by scientists at the Massachusetts Institute of Technology (MIT), also described new cellular pathways that could help the scientific community design new therapies. Four simultaneous studies published on Sept. 28, 2023, in Cell, presented a brain single-cell atlas of AD, exposed the damage that affects DNA, and described the processes that alter the microglia and dysregulate the epigenome.
Kumquat Biosciences Inc. has described heterocyclic compounds and PROTACs acting as GTPase KRAS (G12D, G12C, G12S and G13D mutant), and/or G12V and wild-type GTPase KRAS inhibitors reported to be useful for the treatment of cancer.
Shanghai Zhigen Pharmaceutical Technology Co Ltd. has divulged nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of inflammation and autoimmune diseases.
Shanghaitech University has identified G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of schizophrenia, among others.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has synthesized mast/stem cell growth factor receptor Kit (KIT; c-KIT; CD117) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory and neurological disorders.
Ikena Oncology Inc. has disclosed mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors reported to be useful for the treatment of cancer.